---
schema_version: "secwatch.filing_event.v1"
accession: "0001689548-24-000035"
form_type: "8-K"
ticker: "PRAX"
cik: "0001689548"
company_name: "Praxis Precision Medicines, Inc."
filed_at: "2024-03-05T23:59:59+00:00"
generated_at: "2026-06-05T03:50:56.447438+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Praxis: FY2023 net loss $123.3M; cash $247.6M; ulixacaltamide Phase 3 on track, PRAX-628 topline expected 1Q24

## Summary
- Cash and equivalents $247.6M as of Feb 29, 2024, funded by $161.7M January 2024 follow-on; runway into 2026.
- FY2023 net loss $123.3M vs $214.0M in 2022; R&D expenses fell to $86.8M from $155.0M.
- Essential3 Phase 3 program for ulixacaltamide (ET) has >3,000 pre-qualified referrals; enrollment due 1H24, topline 2H24.
- PRAX-628 PPR study 15 mg cohort exceeded expectations; topline data expected Q1 2024; Phase 2b plan in 2H24.
- Elsunersen (PRAX-222): 43% median seizure reduction in EMBRAVE Part 1; EMA PRIME designation for SCN2A DEE.

## SEC filing metadata
- accession: 0001689548-24-000035
- form_type: 8-K
- ticker: PRAX
- cik: 0001689548
- company_name: Praxis Precision Medicines, Inc.
- filed_at: 2024-03-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689548/000168954824000035/0001689548-24-000035-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689548/000168954824000035/prax-20240305.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001689548-24-000035
- JSON: https://secwatch.observer/filing/0001689548-24-000035.json
- Plain text: https://secwatch.observer/filing/0001689548-24-000035.txt

## Key facts
- Earnings Releases
  Praxis Precision Medicines, Inc. reported financial results for fourth quarter and full-year 2023.
  - Period: fourth quarter and full-year 2023
  - Result: reported results
  source text: On March 5, 2024, Praxis Precision Medicines, Inc. (the “Company”) announced its financial results for the quarter and full year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1689548/000168954824000035/0001689548-24-000035-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.